Aug. 1 Quick Takes: Qiming, Quan lead $120M series B for OriCell
Plus Concert preps JAK1/2 NDA and updates from Otonomy, Stealth and more
Leading Chinese VCs Qiming Venture Partners and Quan Capital led a $120 million series B round for OriCell Therapeutics (Shanghai) Co. Ltd., which will use the cash to support its cell therapy pipeline and build a manufacturing facility. Existing investor C&D Emerging Capital also participated. Founded in 2015 and led by Chairman and CEO Helen Yang, OriCell has discovery platforms for CAR T therapies, antibodies and TILs and at least 20 therapies in its pipeline.
Concert Pharmaceuticals Inc. (NASDAQ:CNCE) plans to submit an NDA to FDA in 1H23 for CTP-543 after the oral inhibitor of JAK 1/2 met the primary endpoint of the Phase III THRIVE-AA study to treat moderate to severe alopecia areata. Concert believes the therapy, which also met secondary endpoints in hair satisfaction and hair regrowth, could be best in class. Concert gained $0.29 to $5.89 on Monday. ...